(MRVI) Maravai Lifesciences - NASDAQ

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.125m USD | Total Return: 161.3% in 12m

Nucleic Acids, Oligonucleotides, ELISA Kits, Bioprocess Reagents
Total Rating 53
Safety 66
Buy Signal 2.03
Biotechnology
Industry Rotation: +21.2
Market Cap: 2.12B
Avg Turnover: 13.9M
Risk 3d forecast
Volatility67.3%
VaR 5th Pctl10.2%
VaR vs Median-7.03%
Reward TTM
Sharpe Ratio1.63
Rel. Str. IBD96.7
Rel. Str. Peer Group95
Character TTM
Beta1.672
Beta Downside1.882
Hurst Exponent0.601
Drawdowns 3y
Max DD86.61%
CAGR/Max DD-0.24
CAGR/Mean DD-0.37
EPS (Earnings per Share) EPS (Earnings per Share) of MRVI over the last years for every Quarter: "2021-06": 0.44, "2021-09": 0.09, "2021-12": 0.45, "2022-03": 0.54, "2022-06": 0.54, "2022-09": 0.37, "2022-12": 0.35, "2023-03": 0.03, "2023-06": -0.05, "2023-09": -0.01, "2023-12": 0.01, "2024-03": -0.02, "2024-06": -0.0558, "2024-09": -0.02, "2024-12": -0.06, "2025-03": -0.21, "2025-06": -0.08, "2025-09": -0.08, "2025-12": -0.04, "2026-03": 0.01,
Last SUE: 2.09
Qual. Beats: 2
Revenue Revenue of MRVI over the last years for every Quarter: 2021-06: 217.775, 2021-09: 204.81, 2021-12: 228.444, 2022-03: 244.293, 2022-06: 242.732, 2022-09: 191.263, 2022-12: 204.713, 2023-03: 79.025, 2023-06: 68.914, 2023-09: 66.865, 2023-12: 74.141, 2024-03: 64.179, 2024-06: 73.4, 2024-09: 65.2, 2024-12: 56.406, 2025-03: 46.85, 2025-06: 47.397, 2025-09: 41.63, 2025-12: 49.866, 2026-03: 65.837,
Rev. CAGR: -27.12%
Rev. Trend: -90.7%
Last SUE: 4.00
Qual. Beats: 1

Warnings

Interest Coverage Ratio Critical
Extended 1w

Tailwinds

Supp Ema8
Rs Leader
Idiosyncratic Leader
Tailwind
Confidence

Seasonality

Coming soon
Description: MRVI Maravai Lifesciences

Maravai LifeSciences Holdings (MRVI) is a U.S.-based life sciences company that supplies critical inputs and analytical tools used by biopharmaceutical developers, diagnostics manufacturers, and academic research institutions. It operates two segments: TRILINK, which manufactures nucleic acid products (DNA, RNA, mRNA, and oligonucleotides) along with CleanCap capping technology and custom enzymes, and CYGNUS, which provides antibody-based analytical products and ELISA kits for detecting impurities in biologic manufacturing. Founded in 2014 and headquartered in San Diego, California, the company went public in November 2020 and operates globally across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin and Central America. As a constituent of the Health Care sectors Life Sciences Tools & Services sub-industry, Maravai sits within the pick-and-shovel supplier ecosystem, providing enabling technologies and consumables rather than developing its own therapeutics.

Headlines to Watch Out For
  • CleanCap mRNA demand drops as COVID vaccine orders fade
  • Biotech funding crunch pressures TRILINK nucleic acid sales
  • CYGNUS bioprocess analytics offsets TRILINK volume decline
Piotroski VR-10 (Strict) 0.0
Net Income: -104.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA -4.80 > 1.0
NWC/Revenue: 102.1% < 20% (prev 129.5%; Δ -27.33% < -1%)
CFO/TA -0.06 > 3% & CFO -39.5m > Net Income -104.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.91 > 1.5 & < 3
Outstanding Shares: last quarter (146.4m) vs 12m ago 2.09% < -2%
Gross Margin: 29.00% > 18% (prev 37.29%; Δ -8.29% > 0.5%)
Asset Turnover: 24.48% > 50% (prev 25.20%; Δ -0.72% > 0%)
Interest Coverage Ratio: -6.27 > 6 (EBIT TTM -162.8m / Interest Expense TTM 26.0m)
Altman Z'' 1.29
A: 0.29 (Total Current Assets 251.7m - Total Current Liabilities 42.6m) / Total Assets 713.2m
B: 0.01 (Retained Earnings 6.38m / Total Assets 713.2m)
C: -0.19 (EBIT TTM -162.8m / Avg Total Assets 836.5m)
D: 0.61 (Book Value of Equity 211.6m / Total Liabilities 344.1m)
Altman-Z'' = 1.29 = BB
Beneish M -2.56
DSRI: 1.39 (Receivables 33.4m/28.5m, Revenue 204.7m/241.9m)
GMI: 1.29 (GM 37.29% / 29.00%)
AQI: 1.01 (AQ_t 0.44 / AQ_t-1 0.43)
SGI: 0.85 (Revenue 204.7m / 241.9m)
TATA: -0.09 (NI -104.6m - CFO -39.5m) / TA 713.2m)
Beneish M = -2.56 (Cap -4..+1) = A
What is the price of MRVI shares?

As of June 29, 2026, the stock is trading at USD 6.22 with a total of 6,261,342 shares traded. Over the past week, the price has changed by +19.62%, over one month by +42.01%, over three months by +101.29% and over the past year by +161.34%.

Current recommended Stop Loss: 5.80 (which is 6.8% or 1.5 ATR below the current price).

Is MRVI a buy, sell or hold?

Maravai Lifesciences has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy MRVI.

  • StrongBuy: 5
  • Buy: 1
  • Hold: 7
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MRVI price?
Analysts Target Price 5.7 -8.4%
Maravai Lifesciences (MRVI) - Fundamental Data Overview as of 27 June 2026
Market Cap USD = 2.12b (2.12b USD * 1.0 USD.USD)
P/E Forward = 370.3704
P/S = 10.3781
P/B = 4.016
Revenue TTM = 204.7m USD
EBIT TTM = -162.8m USD
EBITDA TTM = -103.9m USD
Long Term Debt = 235.6m USD (from longTermDebt, last quarter)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 300.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 29.9m
Net Debt = 134.8m USD (calculated: Debt 300.7m - CCE 165.9m)
Enterprise Value = 2.26b USD (2.12b + Debt 300.7m - CCE 165.9m)
Interest Coverage Ratio = -6.27 (Ebit TTM -162.8m / Interest Expense TTM 26.0m)
EV/FCF = -43.56x (Enterprise Value 2.26b / FCF TTM -51.9m)
FCF Yield = -2.30% (FCF TTM -51.9m / Enterprise Value 2.26b)
FCF Margin = -25.34% (FCF TTM -51.9m / Revenue TTM 204.7m)
Net Margin = -51.07% (Net Income TTM -104.6m / Revenue TTM 204.7m)
Gross Margin = 29.00% ((Revenue TTM 204.7m - Cost of Revenue TTM 145.4m) / Revenue TTM)
Gross Margin QoQ = 51.19% (prev 24.55%)
Tobins Q-Ratio = 3.17 (Enterprise Value 2.26b / Total Assets 713.2m)
Interest Expense / Debt = 8.63% (Interest Expense 26.0m / Debt 300.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -128.6m (EBIT -162.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.91 (Total Current Assets 251.7m / Total Current Liabilities 42.6m)
Debt / Equity = 1.42 (Debt 300.7m / totalStockholderEquity, last quarter 211.6m)
 Debt / EBITDA = -1.30 (negative EBITDA) (Net Debt 134.8m / EBITDA -103.9m)
 Debt / FCF = -2.60 (negative FCF - burning cash) (Net Debt 134.8m / FCF TTM -51.9m)
 Total Stockholder Equity = 233.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -12.50% (Net Income -104.6m / Total Assets 713.2m)
RoE = -44.72% (Net Income TTM -104.6m / Total Stockholder Equity 233.8m)
RoCE = -34.69% (EBIT -162.8m / Capital Employed (Equity 233.8m + L.T.Debt 235.6m))
 RoIC = -19.32% (negative operating profit) (NOPAT -128.6m / Invested Capital 665.8m)
 WACC = 11.24% (E(2.12b)/V(2.43b) * Re(11.86%) + D(300.7m)/V(2.43b) * Rd(8.63%) * (1-Tc(0.21)))
Discount Rate = 11.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 4.67%
 [DCF] Fair Price = unknown (Cash Flow -51.9m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.09 | # QB: 2
Revenue Correlation: -90.73 | Revenue CAGR: -27.12% | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.04 | Chg30d=+5.17% | Revisions=-20% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.05 | Chg30d=+5.68% | Revisions=+20% | Analysts=7
EPS current Year (2026-12-31): EPS=-0.11 | Chg30d=+38.00% | Revisions=+33% | GrowthEPS=+60.4% | GrowthRev=+13.3%
EPS next Year (2027-12-31): EPS=-0.09 | Chg30d=+38.74% | Revisions=+33% | GrowthEPS=+19.0% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: +33%